Orbis Medicines Funding: $125M Raised, Series A (2025)
Orbis Medicines is based in Copenhagen, Denmark. It has raised $125M in total funding. Latest round: Series A.
Orbis Medicines funding overview
Orbis Medicines is based in Copenhagen, Denmark. Orbis Medicines has raised $125M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2025. The round record for Orbis Medicines runs through 2025; nothing later has been disclosed. Investors on record include NEA (New Enterprise Associates), Eli Lilly and Company, Cormorant Asset Management, LP, Export and Investment Fund of Denmark (EIFO), Novo Holdings, Forbion. 6 distinct backers are named across the disclosed rounds.
Orbis Medicines at a glance
Total raised
$125M
Latest round
Series A
Latest round date
January 2025
Headquarters
Copenhagen, Denmark
Notable investors
NEA (New Enterprise Associates), Eli Lilly and Company, Cormorant Asset Management, LP, Export and Investment Fund of Denmark (EIFO), Novo Holdings, Forbion
Frequently asked about Orbis Medicines funding
How much has Orbis Medicines raised?
Orbis Medicines has raised $125M in total disclosed funding across the rounds on record.
Who has invested in Orbis Medicines?
NEA (New Enterprise Associates), Eli Lilly and Company, Cormorant Asset Management, LP, Export and Investment Fund of Denmark (EIFO), Novo Holdings, Forbion are named among the investors backing Orbis Medicines.
What was the latest Orbis Medicines funding round?
The most recent disclosed round is a Series A, announced in January 2025.
Where is Orbis Medicines based?
Orbis Medicines is based in Copenhagen, Denmark.
When did Orbis Medicines last raise?
The last disclosed Orbis Medicines round closed in January 2025 at Series A.
We update the Orbis Medicines record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Copenhagen and their backers are listed below.
